{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:17:20Z","timestamp":1792513040503,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-114-2314-B-567-002"],"award-info":[{"award-number":["NSTC-114-2314-B-567-002"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-113-2314-B-567-001"],"award-info":[{"award-number":["NSTC-113-2314-B-567-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009974","name":"Cardinal Tien Hospital","doi-asserted-by":"publisher","award":["CTH-110A-2217"],"award-info":[{"award-number":["CTH-110A-2217"]}],"id":[{"id":"10.13039\/501100009974","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009974","name":"Cardinal Tien Hospital","doi-asserted-by":"publisher","award":["CTH-112A-2215"],"award-info":[{"award-number":["CTH-112A-2215"]}],"id":[{"id":"10.13039\/501100009974","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009974","name":"Cardinal Tien Hospital","doi-asserted-by":"publisher","award":["CTH-113A-NDMC-2233"],"award-info":[{"award-number":["CTH-113A-NDMC-2233"]}],"id":[{"id":"10.13039\/501100009974","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.eclinm.2026.103923","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:56:25Z","timestamp":1778478985000},"page":"103923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and safety of AAV-mediated gene therapy for choroideremia: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"95","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-3411","authenticated-orcid":false,"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.103923_bib1","first-page":"10","article-title":"Choroideremia\u2013a clinical insight and differential diagnosis","volume":"8","author":"Nouraeinejad","year":"2022","journal-title":"Population"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103923_bib2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/13816810.2024.2357705","article-title":"Exploring the impact of Choroideremia on women with phenotypic and\/or genotypic evidence of disease: insights from a global survey","volume":"45","author":"Bonneau","year":"2024","journal-title":"Ophthalmic Genet"},{"key":"10.1016\/j.eclinm.2026.103923_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajo.2025.07.021","article-title":"Trends and disparities in the incidence and prevalence of inherited retinal diseases in the United States","volume":"279","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103923_bib4","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/genes12081111","article-title":"Molecular characterization of choroideremia-associated deletions reveals an unexpected regulation of CHM gene transcription","volume":"12","author":"Fioretti","year":"2021","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103923_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/humu.24174","article-title":"CHM mutation spectrum and disease: an update at the time of human therapeutic trials","volume":"42","author":"Zeitz","year":"2021","journal-title":"Hum Mutat"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103923_bib6","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.3390\/ijms26083636","article-title":"Genetic analysis of choroideremia-related rab escort proteins","volume":"26","author":"Xing","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103923_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1167\/tvst.10.8.12","article-title":"Expression of Rab prenylation pathway genes and relation to disease progression in Choroideremia","volume":"10","author":"Fry","year":"2021","journal-title":"Transl Vis Sci Technol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.103923_bib8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/08164622.2023.2227766","article-title":"Night blindness and hearing loss associated with choroideremia","volume":"107","author":"Biarn\u00e9s","year":"2024","journal-title":"Clin Exp Optom"},{"issue":"11","key":"10.1016\/j.eclinm.2026.103923_bib9","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/IAE.0000000000002553","article-title":"Choroideremia: retinal degeneration with an unmet need","volume":"39","author":"Pennesi","year":"2019","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103923_bib10","doi-asserted-by":"crossref","first-page":"S564","DOI":"10.1016\/j.jval.2022.04.1467","article-title":"PCR124 patient-reported impact of choroideremia on daily activities, work activities, and healthcare resource utilization","volume":"25","author":"Thompson","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103923_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13023-023-02798-z","article-title":"A multidisciplinary approach to inherited retinal dystrophies from diagnosis to initial care: a narrative review with inputs from clinical practice","volume":"18","author":"Murro","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103923_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/08164622.2021.1880863","article-title":"Gene therapy for inherited retinal diseases: progress and possibilities","volume":"104","author":"Hu","year":"2021","journal-title":"Clin Exp Optom"},{"issue":"12","key":"10.1016\/j.eclinm.2026.103923_bib13","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s40265-025-02237-2","article-title":"Can gene therapy transform the treatment landscape of posterior segment eye diseases? A comprehensive review of recent advancements","volume":"85","author":"Chen","year":"2025","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103923_bib14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.59249\/HWID7537","article-title":"Ocular gene therapy: an overview of viral vectors, immune responses, and future directions","volume":"97","author":"Banou","year":"2024","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.eclinm.2026.103923_bib15","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/OPTH.S364200","article-title":"Ocular gene therapy: a literature review with special focus on immune and inflammatory responses","volume":"16","author":"Ghoraba","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103923_bib16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1089\/hum.2018.027","article-title":"Assessment of AAV vector tropisms for mouse and human pluripotent stem cell\u2013derived RPE and photoreceptor cells","volume":"29","author":"Gonzalez-Cordero","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103923_bib17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol Ther"},{"issue":"14","key":"10.1016\/j.eclinm.2026.103923_bib18","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1089\/104303401750476212","article-title":"Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors","volume":"12","author":"Shi","year":"2001","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.eclinm.2026.103923_bib19","series-title":"Gene Therapy for Choroideremia. Gene-and Cell-Based Treatment Strategies for the Eye","first-page":"27","author":"Barnard","year":"2014"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103923_bib20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/jgm.401","article-title":"Long-term evaluation of retinal function in Prph2Rd2\/Rd2 mice following AAV-mediated gene replacement therapy","volume":"5","author":"Schlichtenbrede","year":"2003","journal-title":"J Gene Med"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103923_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/14712598.2025.2459850","article-title":"Gene therapy for choroideremia: progress, potential and pitfalls","volume":"25","author":"Abdalla Elsayed","year":"2025","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.eclinm.2026.103923_bib22","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.2147\/OPTH.S195564","article-title":"Choroideremia: update on clinical features and emerging treatments","volume":"13","author":"Brambati","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103923_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.eclinm.2026.103923_bib24","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2026.103923_bib25","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103923_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103923_bib27","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2022.06.006","article-title":"Adeno-associated virus serotype 2-hCHM subretinal delivery to the macula in choroideremia: two-year interim results of an ongoing phase I\/II gene therapy trial","volume":"129","author":"Aleman","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eclinm.2026.103923_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","article-title":"Two-year results after AAV2-Mediated gene therapy for choroideremia: the Alberta experience","volume":"193","author":"Dimopoulos","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.eclinm.2026.103923_bib29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","article-title":"Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia","volume":"137","author":"Fischer","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103923_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/IAE.0000000000002360","article-title":"Changes in retinal sensitivity after gene therapy in choroideremia","volume":"40","author":"Fischer","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.eclinm.2026.103923_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","article-title":"Choroideremia gene therapy phase 2 clinical trial: 24-month results","volume":"197","author":"Lam","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"9923","key":"10.1016\/j.eclinm.2026.103923_bib32","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"issue":"15\u201316","key":"10.1016\/j.eclinm.2026.103923_bib33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1089\/hum.2024.017","article-title":"An open-label phase II study assessing the safety of bilateral, sequential administration of retinal gene therapy in participants with choroideremia: the GEMINI study","volume":"35","author":"MacLaren","year":"2024","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103923_bib34","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1038\/s41591-023-02520-3","article-title":"Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial","volume":"29","author":"MacLaren","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103923_bib35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamaophthalmol.2022.0158","article-title":"Short-term assessment of subfoveal injection of adeno-associated virus-mediated hCHM gene augmentation in choroideremia using adaptive optics ophthalmoscopy","volume":"140","author":"Morgan","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.103923_bib36","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41591-018-0185-5","article-title":"Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia","volume":"24","author":"Xue","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2026.103923_bib37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ajo.2022.12.022","article-title":"AAV2-Mediated gene therapy for choroideremia: 5-year results and alternate anti-sense oligonucleotide therapy","volume":"248","author":"Zhai","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103923_bib38","first-page":"4485","article-title":"AAV2-hCHM subretinal delivery to the macula in choroideremia: preliminary six month safety results of an ongoing phase I\/II gene therapy trial","volume":"58","author":"Aleman","year":"2017","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"14","key":"10.1016\/j.eclinm.2026.103923_bib39","first-page":"5577","article-title":"Gene therapy for choroideremia - initial report on a new clinical trial","volume":"53","author":"MacLaren","year":"2012","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103923_bib40","first-page":"1195","article-title":"Retinal gene therapy for choroideremia in a multicenter dose escalation phase I\/II clinical trial","volume":"59","author":"MacLaren","year":"2018","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103923_bib41","first-page":"5173","article-title":"AAV2-hCHM subretinal delivery to the macula in choroideremia: 2 year results of an ongoing phase I\/II gene therapy trial","volume":"60","author":"Aleman","year":"2019","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.eclinm.2026.103923_bib42","article-title":"Long term vision results following retinal gene therapy for choroideremia","volume":"57","author":"MacLaren","year":"2016","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103923_bib43","first-page":"47","article-title":"Cone mosaic integrity in choroideremia following gene augmentation via subretinal injection of AAV2-hCHM","volume":"62","author":"Morgan","year":"2021","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103923_bib44","article-title":"Short-term assessment of subfoveal injection of AAV2-hCHM gene augmentation in choroideremia using adaptive optics ophthalmoscopy","volume":"140","author":"Morgan","year":"2021","journal-title":"bioRxiv"},{"issue":"12","key":"10.1016\/j.eclinm.2026.103923_bib45","article-title":"Ocular gene therapy for choroideremia: the Alberta experience","volume":"57","author":"MacDonald","year":"2016","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103923_bib46","first-page":"3386","article-title":"Choroideremia gene therapy phase II clinical trial: 6-month results","volume":"58","author":"Lam","year":"2017","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.eclinm.2026.103923_bib47","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00109-013-1006-4","article-title":"Functional expression of rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo","volume":"91","author":"Tolmachova","year":"2013","journal-title":"J Mol Med"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103923_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/WARA5730","article-title":"Gene therapy for choroideremia using an adeno-associated viral vector encoding Rab escort protein 1: the REGENERATE open-label trial","volume":"11","author":"Cehajic-Kapetanovic","year":"2024","journal-title":"Efficacy Mech Eval"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103923_bib49","first-page":"2919","article-title":"Vector shedding and immunology measures in a choroideremia gene therapy trial","volume":"60","author":"Barnard","year":"2019","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.eclinm.2026.103923_bib50","first-page":"3318","article-title":"Five-year results after AAV2-REP1 gene therapy for choroideremia","volume":"62","author":"Zhai","year":"2021","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.eclinm.2026.103923_bib51","first-page":"6401","article-title":"Subfoveal gene augmentation therapy for choroideremia: one-year results from a Phase I\/II trial of AAV2-hCHM","volume":"60","author":"Huckfeldt","year":"2019","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.eclinm.2026.103923_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061396","article-title":"AAVmediated gene therapy for choroideremia: preclinical studies in personalized models","volume":"8","author":"Vasireddy","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.eclinm.2026.103923_bib53","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.eclinm.2026.103923_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1607","article-title":"Optimization strategies and advances in the research and development of AAV-based gene therapy to deliver large transgenes","volume":"14","author":"Kolesnik","year":"2024","journal-title":"Clin Transl Med"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103923_bib55","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1186\/s12967-024-05661-2","article-title":"Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside","volume":"22","author":"Xu","year":"2024","journal-title":"J Transl Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026001719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:44:43Z","timestamp":1783172683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026001719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":55,"alternative-id":["S2589537026001719"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103923","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of AAV-mediated gene therapy for choroideremia: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103923"}}